Dr. Adnan Mansoor
Dr Mansoor is a Professor of Pathology/ Laboratory Medicine, University of Calgary and consultant Hematopathologist, Alberta Precision Laboratory. He leads provincial lymphoma specialty group in Alberta. An active volunteer with Royal College of Physicians and Surgeons of Canada, as chair, exam committee in General Pathology. He served as division head in Hematopathology at Calgary Laboratory Services ( CLS) (2004 to 2014).
Dr Mansoor completed Fogarty visiting fellowship at Hematopathology section, NIH, Bethesda, MD USA (1994-1996) and his AP/CP residency at The George Washington University, Washington DC, USA (1996-2000). His hematopathology fellowship training was at MD Anderson Cancer Ctr, University of Texas, Houston TX USA (2000-2001). Dr Mansoor is actively involved in translational research related to hematological malignancies. He has published 47 research articles in peer reviewed journals and presented more than 75 research papers at national and international conferences.
Dr. Emina Torlakovic
Dr. Emilia Torlakovic obtained her M.D. at the University of Zagreb and her Ph.D. at the University of Oslo. She is board certified by The American Board of Pathology in Anatomic and Clinical Pathology with subspecialty boards in Hematopathology. She is a founding member of the NordiQC, has co-founded CIQC, and also founded Canadian Biomarker Quality Assurance and CBQAReadout.ca academic QA programs, which she is currently directing. Dr. Torlakovic is the Chair of the National Standards Committee for High Complexity Testing of the Canadian Association of Pathologists. She was/is a member of the ASCO/CAP expert panel that published guidelines for hormone receptor testing in breast cancer in 2010 and also an updated guideline in 2020. She is the President of the International Society for Immunohistochemistry and Molecular Morphology and a Board Member of the International Quality Network for Pathology. She is currently a Division Head of Laboratory Hematology in Saskatoon.
Dr. Mansoor’s presentation will outline the concept and basis of the cell of origin (COO) based classification of Diffuse large B-cell lymphoma (DLBCL). It will outline why COO based classification is important for patient care, as well as the various platforms available to allocate DLBCL cases into distinct COO classification. I will also present the limitation and advantages of various laboratory platforms.
- Understand the clinical application of Cell of origin based classification of DLBCL
- Know what is Hans Algorithm and its limitation
- How we can improve the efficiency of Hans Algorithm in pathology practice.
- What are therapeutic benefits of Cell of Origin based classification of DLBCL
- Participants will be able to position the relevance of COO and Hans’ Algorithm for DLBCL.
- Participants will be able to select the appropriate readout cut off for their assay analytical sensitivity.
- Participants will be able to position the role of pathologists’ readout to overall sensitivity and specificity of the testing.